Join us for a 60-minute discussion on the role of TEVIMBRA (tislelizumab-jsgr), a *** optimize PD-1 binding and deliver more robust T-cell activation.
Using a case-based approach, we will explore key clinical data and discuss treatment decision-making as well as key considerations for optimizing patient care.
This session is designed for medical oncologists and other healthcare professionals to deepen their understanding of TEVIMBRA and its use in the management of ESCC and GC/GEJC.
TO RSVP: click here to see the flyer on how to register
Or by contacting:
Linh Jester
(206) 945-8138
linh.jester@beonemed.com
Please register by scanning the code or using the link below:
CLICK HERE